FLC
OACC

Fifth Lane Capital’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Fifth Lane Capital’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,000
Closed -$356K – 124
2025
Q2 		$356K Buy
+34,000
New +$353K 0.43% 37

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fifth Lane Capital's OACC Position: Q3 2025 in Review

Fifth Lane Capital sold out of Oaktree Acquisition Corp III Life Sciences (OACC) in Q3 2025, closing a stake of 34,000 shares — an estimated $356K sold.

Fifth Lane Capital first reported a position in OACC in Q2 2025 and held it in 1 quarter. The position peaked at $356K in Q2 2025. 48 funds tracked by Wall St. Rank hold OACC as of Q3 2025.

  • Fifth Lane Capital reported no remaining Oaktree Acquisition Corp III Life Sciences position as of Q3 2025 after selling out during the quarter.
  • Fifth Lane Capital sold 34,000 Oaktree Acquisition Corp III Life Sciences shares in Q3 2025, an estimated $356K.
  • Fifth Lane Capital first reported a position in Oaktree Acquisition Corp III Life Sciences in Q2 2025 and held it in 1 quarter.
  • Fifth Lane Capital's Oaktree Acquisition Corp III Life Sciences position peaked at $356K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q3 2025.

Based on Fifth Lane Capital's 13F filing for Q3 2025, filed 12 Nov 2025.